{
    "ticker": "AVXC",
    "name": "Avenue Therapeutics, Inc.",
    "description": "Avenue Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of neurological disorders. Founded in 2016, Avenue is dedicated to addressing unmet medical needs through the development of novel drug formulations. The company\u2019s lead product candidate, IV Tramadol, is an intravenous formulation of the analgesic tramadol, specifically designed for use in hospitals and healthcare settings. This product aims to provide effective pain management while minimizing the risks associated with opioid use. Avenue Therapeutics is committed to advancing the science of pain management and improving patient outcomes by leveraging its expertise in drug development and clinical research. The company is also exploring additional therapeutic candidates that target various neurological conditions, with the goal of enhancing the quality of life for patients suffering from these disorders. Avenue's mission is to bring innovative and safe therapeutic options to market that can significantly improve patient care and address critical healthcare challenges.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2016",
    "website": "https://www.avenuetx.com",
    "ceo": "Lucy Lu",
    "social_media": {
        "twitter": "https://twitter.com/AvenueTx",
        "linkedin": "https://www.linkedin.com/company/avenue-therapeutics"
    },
    "investor_relations": "https://www.avenuetx.com/investors",
    "key_executives": [
        {
            "name": "Lucy Lu",
            "position": "CEO"
        },
        {
            "name": "Michael S. Gorman",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pain Management",
            "products": [
                "IV Tramadol"
            ]
        }
    ],
    "seo": {
        "meta_title": "Avenue Therapeutics, Inc. | Innovative Pain Management Solutions",
        "meta_description": "Explore Avenue Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for neurological disorders, focused on improving pain management.",
        "keywords": [
            "Avenue Therapeutics",
            "IV Tramadol",
            "Pain Management",
            "Neurological Disorders",
            "Biopharmaceutical"
        ]
    },
    "faq": [
        {
            "question": "What is Avenue Therapeutics known for?",
            "answer": "Avenue Therapeutics is known for its development of IV Tramadol for pain management and its focus on neurological disorders."
        },
        {
            "question": "Who is the CEO of Avenue Therapeutics?",
            "answer": "Lucy Lu is the CEO of Avenue Therapeutics, Inc."
        },
        {
            "question": "Where is Avenue Therapeutics headquartered?",
            "answer": "Avenue Therapeutics is headquartered in New York, New York, USA."
        },
        {
            "question": "What is Avenue Therapeutics' lead product?",
            "answer": "Avenue Therapeutics' lead product is IV Tramadol, an intravenous formulation for pain management."
        },
        {
            "question": "When was Avenue Therapeutics founded?",
            "answer": "Avenue Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "PFE",
        "JNJ",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "MRNA",
        "VRTX"
    ]
}